The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COSTEM 2022 | Choosing the right CAR-T therapy for R/R DLBCL
Marion Subklewe, MD, Ludwig-Maximilians-University of Munich, Munich, Germany, discusses the benefits of not preferencing a CD19 CAR construct in patients with relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL). Lymphodepleting regimens can vary depending on the specific CAR-T, and the disease and patient characteristics will have an impact on outcomes. Prof. Subklewe additionally highlights propensity score matching and personalized approaches to enhance survival in patients. This interview took place at the 7th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
